PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
PAVmed (Nasdaq: PAVM, PAVMZ), a commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for November 14, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present third quarter 2024 financial results.
U.S. callers can join via 1-800-836-8184, while international participants should dial 1-646-357-8785. The webcast will be accessible through the company's investor relations website at pavmed.com, with a 30-day replay available afterward.
PAVmed (Nasdaq: PAVM, PAVMZ), una società di tecnologia medica in fase commerciale, ha annunciato una conferenza telefonica di aggiornamento aziendale e un webcast programmato per 14 novembre 2024, alle 8:30 AM ET. Durante la chiamata, il Presidente e CEO Lishan Aklog, M.D., discuterà delle operazioni aziendali e della strategia di crescita, mentre il Presidente e CFO Dennis McGrath presenterà i risultati finanziari del terzo trimestre 2024.
I chiamanti degli Stati Uniti possono unirsi componendo il numero 1-800-836-8184, mentre i partecipanti internazionali dovrebbero comporre il numero 1-646-357-8785. Il webcast sarà accessibile tramite il sito web delle relazioni con gli investitori della società all'indirizzo pavmed.com, con una registrazione disponibile per 30 giorni dopo.
PAVmed (Nasdaq: PAVM, PAVMZ), una empresa de tecnología médica en etapa comercial, ha anunciado una conferencia telefónica de actualización empresarial y una transmisión por web programada para el 14 de noviembre de 2024, a las 8:30 AM ET. Durante la llamada, el Presidente y CEO Lishan Aklog, M.D., discutirá las operaciones de la empresa y la estrategia de crecimiento, mientras que el Presidente y CFO Dennis McGrath presentará los resultados financieros del tercer trimestre de 2024.
Los interesados en Estados Unidos pueden unirse marcando el 1-800-836-8184, mientras que los participantes internacionales deben marcar el 1-646-357-8785. La transmisión web estará disponible a través del sitio web de relaciones con inversionistas de la empresa en pavmed.com, con una repetición disponible durante 30 días después.
PAVmed (Nasdaq: PAVM, PAVMZ), 상업 단계의 의료 기술 회사가 2024년 11월 14일 오전 8시 30분 ET에 예정된 사업 업데이트 컨퍼런스 콜 및 웹캐스트를 발표했습니다. 이번 전화 통화에서 의장 겸 CEO 리샨 아클로그(M.D.)는 회사 운영 및 성장 전략에 대해 논의하며, 사장 겸 CFO 데니스 맥그라스는 2024년 3분기 재무 결과를 발표할 것입니다.
미국의 전화 참여자는 1-800-836-8184로 연결할 수 있으며, 국제 참가자는 1-646-357-8785로 전화해야 합니다. 웹캐스트는 pavmed.com의 회사 투자자 관계 웹사이트를 통해 접근할 수 있으며, 이후 30일간 재생할 수 있습니다.
PAVmed (Nasdaq: PAVM, PAVMZ), une entreprise de technologie médicale en phase commerciale, a annoncé un appel de conférence et un webcast de mise à jour des affaires prévu pour le 14 novembre 2024, à 8h30 ET. Lors de cet appel, le président et CEO Lishan Aklog, M.D., discutera des opérations de l'entreprise et de la stratégie de croissance, tandis que le président et CFO Dennis McGrath présentera les résultats financiers du troisième trimestre 2024.
Les appelants des États-Unis peuvent participer en composant le 1-800-836-8184, tandis que les participants internationaux doivent composer le 1-646-357-8785. Le webcast sera accessible via le site web des relations investisseurs de l'entreprise à pavmed.com, avec un replay disponible pendant 30 jours par la suite.
PAVmed (Nasdaq: PAVM, PAVMZ), ein in der Handelsphase befindliches Medizintechnikunternehmen, hat eine Telefonkonferenz zur Unternehmensaktualisierung und einen Webcast für den 14. November 2024, um 8:30 Uhr ET angekündigt. Während des Anrufs wird der Vorsitzende und CEO Lishan Aklog, M.D., die Unternehmensoperationen und Wachstumsstrategie besprechen, während der Präsident und CFO Dennis McGrath die finanziellen Ergebnisse des dritten Quartals 2024 präsentieren wird.
Anrufer aus den USA können unter 1-800-836-8184 teilnehmen, während internationale Teilnehmer die Nummer 1-646-357-8785 wählen sollten. Der Webcast wird über die Investor Relations-Website des Unternehmens unter pavmed.com zugänglich sein, mit einer 30-tägigen Wiederholung, die anschließend zur Verfügung steht.
- None.
- None.
Conference Call and Webcast at 8:30 AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
For more and for more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-a-business-update-conference-call-and-webcast-on-november-14-2024-302291561.html
SOURCE PAVmed Inc.
FAQ
When is PAVmed's Q3 2024 earnings call scheduled?
How can investors access PAVmed's November 14 conference call?
How long will PAVmed's Q3 2024 earnings call replay be available?